Caveolin-1 (CAV-1) is the principal component of caveolae that regulates a variety of signaling molecules and receptors. Our previous study revealed CAV-1 reduction in the epidermis of patients with psoriasis, which leads to enhanced Janus kinase/signal transducer and activator of transcription activation and cytokine production, suggesting that aberrant CAV-1 expression may contribute to psoriatic inflammation. This study aimed to investigate whether abnormal modulation of CAV-1 on immune cells is involved in the pathogenesis of psoriasis. We observed that CAV-1 level in psoriasis patients was apparently reduced in peripheral blood mononuclear cells (PBMCs) and it was prominent in CD14+ monocytes. CAV-1 silencing in monocytes represented elevated levels of interleukin (IL)-1β and IL-6, and those had enhanced chemotaxis activity. In a murine model of psoriasis-like inflammation induced by imiquimod, we observed a significant CAV-1 reduction in PBMCs. Systemic administration of CAV-1 scaffolding domain peptide significantly improved the skin phenotype with less macrophage infiltration. Taken together, aberrant CAV-1 expression in monocytes may be involved in the pathogenesis of psoriasis.
Psoriasis vulgaris is a chronic immune-mediated inflammatory skin disease characterized by scaly papulosquamous plaque lesions1. The pathogenesis of psoriatic tissue hyperplasia is speculated to be driven by the interactions of various immune cells including macrophages, dendritic cells, and pathogenic and resident memory T cells, with enhanced representation of the interleukin (IL)-23–T helper type 17 (Th17)/ T helper type 22 (Th22) and IL-12– interferon (IFN)-γ/tumour necrosis factor (TNF)-α pathways2.
Caveolin-1 (CAV-1) is a 22-kDa membrane protein essential for the formation of caveolae, which serves as a signaling platform for processes such as lipid metabolism, endocytosis, and signal transduction. CAV-1 downregulates signaling molecules and receptors, which interact with the CAV-1 scaffolding domain (CSD) corresponding to amino acids 82–101 of CAV-1. We previously reported a significant reduction of CAV-1 in the epidermis of patients with psoriasis. A reduction of CAV-1 induces activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in psoriatic inflammation. This activation leads to further keratinocyte proliferation and cytokine/chemokine production3. Furthermore, we observed significant CAV-1 reduction within the epidermal hyperplasia of imiquimod (IMQ)-induced murine model of psoriasis-like skin inflammation and restoration of CAV-1 function in this mice improved skin phenotype.
CAV-1 is also identified in various immune cells, including monocytes/macrophages, polymorphonuclear cells (PMNs), mast cells, and lymphocytes4,5,6,7. Recently, CAV-1 has been implicated as a modulator of innate immunity and inflammation. CAV-1 inhibits the expression of pro-inflammatory cytokines from macrophages by regulating the activation of mitogen-activated protein kinase (MAPK) family members8. Some studies reported that reduction of CAV-1 in immune cells is implicated in various human diseases, fibrotic lung diseases, graft versus host disease, atherosclerosis, and diabetic neuropathy9,10,11,12. In this study, we hypothesized that abnormal CAV-1 level not only in keratinocytes but also in leukocytes may be involved in the pathogenesis of psoriasis. Therefore, we evaluated CAV-1 levels in leukocytes of patients with psoriasis and investigated their roles in the pathogenesis of psoriasis.
CAV-1 is downregulated in PBMCs and PMNs of patients with psoriasis
We first evaluated CAV-1 levels in leukocytes of patients with psoriasis. mRNA expression and protein level of CAV-1 were determined using quantitative polymerase chain reaction (qPCR) and immunoblotting in peripheral blood mononuclear cells (PBMCs) and PMNs. PBMCs and PMNs were isolated from patients with psoriasis vulgaris, who had no history of biologic use and no current use of immunosuppressant, and from healthy subjects. As shown in Fig. 1, CAV-1 mRNA expression in PBMCs (Fig. 1a) and PMNs (Fig. 1b) of patients with psoriasis was significantly reduced compared with that of healthy subjects (P = 0.022, P = 0.047, respectively). Similarly, CAV-1 protein level in PBMCs of patients with psoriasis was significantly decreased compared with that of controls (Fig. 1c, P = 0.025). In PMNs, CAV-1 protein levels varied in healthy subjects. We found a trend towards reduced CAV-1 protein level in the PMNs of patients with psoriasis, but the difference did not reach statistical significance (Fig. 1d, P = 0.151). Therefore, we focused more on PBMCs and conducted further experiments. In some patients with psoriasis who were treated with biologics, CAV-1 expression in PBMCs was serially analysed before and after treatments. Interestingly, recovery of CAV-1 level in PBMCs was observed as clinical improvement by treatments (Fig. 1e, P = 0.002 in total, P = 0.016 in patients treated with TNF-α inhibitors).
CAV-1 reduction is predominant in CD14+ monocytes
To evaluate which type of cells was important in CAV-1 downregulation, immunofluorescent staining of PBMCs was performed and CAV-1 intensities quantified by fluorescent microscopy were compared between patients with psoriasis and controls in CD3+ T cells, CD19+ B cells, and CD14+ monocytes. As shown in Fig. 2a,b, the levels of CAV-1 intensity in each type of cells in patients with psoriasis were lower than those in controls (reduction rate: 17 ± 10%, 16 ± 20%, and 43 ± 14% in T cells, B cells, and monocytes, respectively). Since CAV-1 reduction was most prominent in circulating monocytes, we confirmed that CAV-1 mRNA and protein levels in monocytes were purified from PBMCs of patients with psoriasis in comparison with those of healthy subjects by qPCR and immunoblotting. CAV-1 levels in monocytes of patients with psoriasis were significantly decreased compared with those of controls (Fig. 2c,d, P = 0.001, P = 0.002, respectively). To evaluate if CAV-1 levels in monocytes directly represent clinical parameters in psoriasis patients, we analysed correlations between CAV-1 expression levels in monocytes and clinical features, such as Psoriasis Area and Severity Index (PASI) score, body mass index (BMI), and disease duration in psoriasis patients. As shown in Fig. 2e, there were no correlations between monocyte CAV-1 levels and PASI score or BMI, but CAV-1 levels negatively correlated with disease duration (r = −0.011, P = 0.98, r = −0.078, P = 0.855, r = −0.747, P = 0.033, respectively, Fig. 2e).
Enhanced levels of inflammatory cytokines in CAV-1-silenced monocytes
In our previous findings, reduced CAV-1 level in psoriatic keratinocytes enhances the activation of several signaling molecules and increases cytokine/chemokine productions3. Therefore, we hypothesized that CAV-1 reduction in monocytes may also influence the pathogenesis of psoriasis by modulating cytokine production. CAV-1 was silenced in primary human monocytes by RNA interference, and gene expression levels of psoriasis-related cytokines induced by lipopolysaccharide (LPS) were evaluated using qPCR. As shown in Fig. 3, the mRNA expression levels of IL-1β and IL-6 in CAV-1-silenced monocytes were significantly increased compared with those in control monocytes (Fig. 3a, P = 0.003, P = 0.0002, respectively). However, no differences were observed in the levels of TNF-α and IL-10, and IL-17A expression was undetected (data not shown). We also measured levels of IL-1β and IL-6 released into the supernatants. The levels of IL-6 in supernatants of CAV-1-silenced monocyte were significantly increased compared with those in controls (Fig. 3b, P = 0.045), although those IL-1β levels were found to be increased, but it did not reach statistically significant (Fig. 3b, P = 0.418).
Increased migration activity in CAV-1-silenced monocytes
Infiltration of macrophages and high monocyte chemotactic protein (MCP)-1 expression level were found in psoriasis lesional skin13,14. Hence, we evaluated whether a reduction of CAV-1 is involved in monocyte infiltration to dermis. Chemotaxis assay using CAV-1 silenced monocytes toward MCP-1 was performed. The ratio of migrated cells in CAV-1-silenced monocytes was significantly higher than that in control monocytes (Fig. 4, P = 0.0005). Taken these results together, downregulated CAV-1 in monocytes may have pathophysiological function, e.g., exacerbated migration and enhanced pro-inflammatory cytokine production.
Systemic administration of CSD peptide improves the skin phenotype in IMQ-induced murine model of psoriasis-like skin inflammation
CAV-1 reduction is found in the epidermis of a murine model of psoriasis-like inflammation induced by IMQ, and intradermal injection of CSD peptide improves skin phenotype3. CSD peptides can cross the plasma membrane as they are synthesized by fusion to the antennapedia internalization sequence15. They reverse the effects of CAV-1 depletion in many systems by substituting for the full-length molecule. Since diminished CAV-1 level was observed not only in the epidermis but also in leukocytes of patients with psoriasis, we hypothesized that an aberrant expression of CAV-1 is present in leukocytes of this mouse model. We also hypothesized that systemic administration of CSD peptide may influence clinical phenotype by modulating CAV-1 level of immune cells. Intraperitoneally administered CSD peptide significantly improved skin phenotype compared with control peptide-treated mice (Fig. 5a,b). Histological analysis revealed that epidermal thickness and number of infiltrating cells were greatly reduced in the CSD mice (Fig. 5c,d). Moreover, systemic CSD treatment significantly decreased cytokine expressions, TNF-α, IL-17A, and IL-23p19, in the skin compared with the controls (Fig. 5e, P = 0.022, P = 0.04, and P = 0.018, respectively). We next evaluated CAV-1 expressions of epidermis and leukocytes in these mice. Supporting our previous study, IMQ treatment apparently reduced CAV-1 level in the epidermis as seen in the immunohistochemical analysis, and CAV-1 level was restored by systemic CSD treatment (Fig. 5f). Notably, IMQ treatment also significantly suppressed CAV-1 expression in PBMCs (P = 0.047), and its level tended to be improved by CSD administration (Fig. 5g). This result suggests that abnormality of CAV-1 level in leukocytes is involved in vivo in IMQ-induced psoriasis-like mouse model. To clarify the participation of monocytes/macrophages in this model, we further evaluated infiltrated dermal macrophages in association with CAV-1. As shown in Fig. 6a,b, the number of F4/80+ dermal macrophages was evidently increased by IMQ application. Meanwhile, CSD treatment significantly suppressed its infiltration (P < 0.0001). Furthermore, the fluorescent intensity of CAV-1 in F4/80+ cells was assessed using immunofluorescent microscopy. Infiltrated dermal macrophages had clearly less CAV-1 signal in IMQ-treated mice than in control mice (Fig. 6c, P = 0.0007). However, in CSD mice, CAV-1 signal in macrophages may be higher than that in IMQ mice. No significant differences were found among treatment groups. Additionally, to confirm the efficacy of systemically administrated CSD in another psoriasis-like skin inflammation, an IL-23-induced psoriasis-like murine model was used. We again observed that intraperitoneally administered CSD peptide significantly improved skin phenotype (Supplementary Fig. S1). This result suggests that CAV-1 abnormality is also involved in vivo in IL-23-induced psoriasis-like skin inflammation.
The present study is the first to demonstrate that CAV-1 expression is downregulated not only in keratinocytes but also in leukocytes/monocytes of patients with psoriasis and the murine model. It also showed that diminished CAV-1 in monocytes may modulate cell behaviour in a manner that promotes psoriasis pathology by augmenting cytokine production and migration activity.
With regard to trigger for reduced CAV-1 level, we previously proposed that psoriasis-related cytokines themselves downregulated CAV-1 expression in keratinocytes. Similarly, in monocytes and other cell types, several studies showed that CAV-1 expression is inhibited by TNF-α, transforming growth factor-β, and IL-17A in other pathologies3,9,16. Since such psoriasis-related pro-inflammatory cytokines were high in the serum of patients with psoriasis17,18,19, it may be reasonable that a cytokine-rich environment in psoriasis would favour CAV-1 reduction in leukocytes/monocytes. In this regard, cytokine removal by biologics in patients with psoriasis resulted in increased CAV-1 level in PBMCs with clinical improvement in this study. Interestingly, we found an inverse correlation between CAV-1 levels in monocytes and disease duration in psoriasis patients. As disease duration is closely involved in the process of prolonged systemic inflammation, CAV-1 deficiency in monocytes may directly contribute to the chronicity of psoriatic inflammation.
The pathophysiological contribution of monocytes in the pathogenesis of psoriasis is not completely elucidated, but monocytes are speculated to play pivotal roles. Monocytes from patients with psoriasis are known to overproduce cytokines (e.g., TNF-α, IL-1β, IL-6, and IL-8)20,21. They are highly sensitive to tiny stimuli as a small amount of LPS could induce inflammatory cytokines in comparison with healthy monocytes22. The recent study by Yamanaka et al. revealed that the percentage of CD14high activated monocytes, which release high levels of TNF-α, IL-6, and IL-10, is increased in patients with severe psoriasis compared to those with moderate psoriasis and normal controls. Anti-TNF-α therapy normalizes the ratio of activated monocytes but does not affect cytokine production on lymphocytes, suggesting the importance of monocytes as a contributor to the clinical condition of psoriasis23. We observed that CAV-1-reduced monocytes exacerbated the production of psoriasis-related inflammatory cytokines (IL-1β and IL-6). In this regard, several lines of evidence revealed that CAV-1 interacts with various signaling molecules and negatively regulates those signaling in many types of cells and tissues, and downregulated CAV-1 directly potentiates signaling in many pathologies3,24. Predictably, hyperactivation of several members of the MAPK family of signaling molecules (ERK, JNK, p38) was also observed in CAV-1-reduced monocytes from scleroderma patients9. Therefore, the activated signaling molecules as a result of CAV-1 downregulation in monocytes are presumed to lead to overproduction of inflammatory cytokines in our study.
Infiltration of monocytes/macrophages in lesional skin is a hallmark of psoriasis. We observed that the migration activity toward MCP-1 was enhanced in CAV-1-silenced monocytes in vitro and CSD peptides diminished macrophage infiltration in vivo in a mouse model. These results partially contradict the results of a study by Yi Fu et al.25. They reported that CAV-1 overexpression in THP-1 monocytes inhibits transmigration toward MCP-1, however, CAV-1 knockdown did not have any effect on transmigration in their model. Although the exact reason for this discrepancy remains unclear, there are several possible reasons that may have caused it; e.g. the difference in type of cells (THP-1 or primary monocyte), the proportion of CAV-1-reduced cells induced by transfection, and other methodological differences (used cell numbers, incubation time, and procedures). Elevated MCP-1 expression level was found in psoriasis skin13,26. CCR2, a receptor for MCP-1, is also overexpressed in monocytes and macrophages of patients with psoriasis27. The interaction of MCP-1 and CCR2 is supposed to be crucial in trafficking monocytes into psoriatic skin lesions28. Our observation implies that CAV-1 reduction on monocytes may be responsible for augmentation or maintenance of this system. Monocytes infiltrate into the skin while differentiating into a part of macrophages in peripheral tissues. Macrophages are central regulators of immune response under various pathologies, and their differentiation and behaviour are largely thought to be regulated by soluble factors in the microenvironment. How CAV-1 reduction in psoriatic monocytes affects macrophage differentiation and its function remains unknown. In this regard, Pavlides et al. reported that bone marrow-derived macrophages from CAV-1 deficient mice are more susceptible to apoptosis and more prone to induce inflammation29. This finding may suggest that diminished CAV-1 monocytes may be a source of inflammatory macrophages in psoriasis. On the other hand, a recent study showed that CAV-1 deficiency in monocytes may inhibit macrophage differentiation25. Because monocyte-derived macrophages serve various function, further studies are required to clarify the role of CAV-1 on monocytes/macrophages in the circumstance of psoriasis milieu. In particular, CAV-1 deficiency on monocytes seems to be implicated on atherosclerosis; the association of CAV-1 impairment and psoriasis comorbidity may be a prospective study with great interest.
Given the association between reduced CAV-1 expression and psoriatic inflammation in human monocytes, we investigated the effect of manipulating CAV-1 function using CSD peptides in vivo in mice experiments. We have previously administrated CSD peptide intradermally at the same area of the IMQ topical site to determine the direct response of CSD to lesional keratinocytes3. In the present study, we focused on CAV-1 deficiency on leukocytes/monocytes and their contribution to psoriatic inflammation, therefore CSD was systemically administrated by intraperitoneal injection to avoid direct contact with lesional keratinocytes. A significant suppression of CAV-1 level in PBMCs was validated in IMQ-treated mice, and functional recovery of CAV-1 by intraperitoneal administration of CSD peptides not only improved the cutaneous phenotype, but also reduced the number of infiltrated dermal macrophages. However, our study shows the possibility that decreased infiltration of dermal macrophage may not be due solely to the effect of CSD peptide on monocytes but also the secondary effect of skin improvement. Moreover, we believe that CAV-1 deficiency in both keratinocytes and monocytes, at least in part, participates and coordinates in the formation and maintenance of psoriatic skin lesions, but it is unclear which cells are dominant contributors to psoriatic skin formation. This is a limitation of our study and further experiments are desired using transgenic mice in which CAV-1 was knocked out specifically on the skin or monocytes in order to clarify the direct contribution of each.
Previous reports showed that CSD peptides do not affect CAV-1 expression, and CSD peptides themselves are not detected as they are only a short functional domain of CAV-1 and only mimic CAV-1 function30,31. However, we observed that CAV-1 expression tended to be reversed by administering CSD peptides in PBMCs, but no such tendency was found in dermal macrophages. Although the reason for this variation on CAV-1 level caused by CSD treatment is unclear, several reasonable explanations exist regarding our observation. First, treatment with CSD peptides ameliorated psoriasis inflammation, which was a trigger for CAV-1 downregulation. Thus, CAV-1 level was reversed as a consequence of elimination of the cause for CAV-1 inhibition in the blood. Second, CAV-1-reduced monocytes had higher migration activity. Hence, the absence of difference is reasonable in CAV-1 level on dermal macrophages after CSD treatment, as those cells were already migrated because of reduced CAV-1 level. Third, a study reported that CAV-1 expression is elevated after monocyte-to-macrophage differentiation in both immortalized and primary cells25. CAV-1 level was also possibly altered during differentiation in our experiments.
In summary, our study suggested that CAV-1 reduction in circulating monocytes of patients with psoriasis may play a role in the pathogenesis of psoriasis by enhancing cytokine production and promoting monocyte infiltration into the skin. Furthermore, recovery of CAV-1 function by systemic administration of CSD peptides improved skin phenotype through adjustment of skin infiltration of macrophages, demonstrating that CAV-1 may be a therapeutic target.
Materials and Methods
Twenty patients who were diagnosed with psoriasis vulgaris were included in the study. Blood and skin samples were obtained from patients with psoriasis who had no current immunosuppressive medications and no history of biologics. Serial samples were collected before treatment and after clinical improvement by biologics in some patients. Clinical features of patients are shown in Supplementary Tables S1 and S2. Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. All methods were carried out in accordance with the relevant guidelines and regulations. The study was approved by the Institutional Review Board of Yokohama City University (Approval No: B120705021).
Peripheral blood samples were collected, and PBMCs and PMNs were isolated by density centrifugation at 700 g for 30 min using Histopaque® 1119 and 1077 (Sigma-Aldrich, St Louis, MO). Separated cell layers were suspended in RPMI 1640 (Wako Pure Chemical Industries, Osaka, Japan). Human primary monocytes were purified from PBMCs using the Monocyte Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of isolated monocytes was more than 85% and validated through the expression of CD14 by flow cytometry (Supplementary Fig. S2). Cell suspensions were prepared for immunoblotting and PCR analyses as appropriate.
Semi-quantitative and quantitative polymerase chain reaction (qPCR)
Total RNA was extracted using TRIzol® and the IllustraTM RNAspin Mini RNA Isolation Kit (GE Healthcare, Uppsala, Sweden), and qPCR was performed in duplicate using TaqMan® gene expression assays or the Thunderbird® SYBR® qPCR Mix (Toyobo, Osaka, Japan) as previously described3. Gene expression levels were normalized to β-actin or GAPDH and compared using the 2−ΔΔCt method. TaqMan® probes for human CAV-1, TNF-α, IL-1β, IL-17A, IL-6, IL-10, and β-actin, mouse β-actin, and CAV-1 were obtained from Applied Biosystems (Carlsbad, CA); the assay identification numbers are shown in Supplementary Table S3. The primer sets used for semi-quantitative PCR and SYBR qPCR are shown in Supplementary Table S4.
Samples were prepared using radioimmunoprecipitation assay buffer containing a protease inhibitor cocktail as previously described32. Equal quantities of protein were analysed by immunoblotting using one of the following antibodies: CAV-1 (Santa Cruz Biotechnology, Santa Cruz, CA) and GAPDH (Cell Signaling). Signals were detected using horseradish peroxidase-conjugated secondary antibody and ECLTM Prime Western Blotting Detection Reagent (GE Healthcare).
PBMCs were collected by cytospin and stained using the indicated primary antibodies. Cells were fixed with 2% paraformaldehyde and then permeabilized with 0.1% Triton X-100. Cells were incubated with Alexa Flour® 647-conjugated anti-CD3, CD14, or CD19 (BioLegend, San Diego, CA), and anti-CAV-1 (Santa Cruz Biotechnology), followed by Alexa Flour® 488-conjugated secondary IgG (Invitrogen, Grand Island, NY). Appropriate isotype IgG was used as a control. ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole (DAPI; Life Technology, Carlsbad, CA) was used for nuclear identification and mounting. The intensity of CAV-1 staining was quantified in randomly chosen CD3+ T cells, CD19+ B cells, and CD14+ monocytes. The data were obtained from 20 cells from each three patients and healthy subjects. Images were taken and analysed using an Olympus Fluoview 1000 microscope (Olympus America, Melville, NY) and fixed camera settings.
Purified monocytes (3 × 105) were seeded on a 24-well multidish (Thermo Fisher Scientific, Rochester, NY) in RPMI-1640 supplemented with 10% foetal bovine serum. CAV-1-specific small-interfering RNA (Stealth RNAi) and control RNAi were purchased from Invitrogen. For transfection, Viromer® Green (Lipocalyx GmbH, Halle (Saale), Germany) was used in accordance with the manufacturer’s instructions. A mixture of 50 pM of each RNAi and Viromer® was added to cells, and cells were cultured for 24 h. Serum was starved at least 6 h before further stimulation. CAV-1-silenced or controlled monocytes were cultured supplemented with 50 ng/mL LPS (Sigma-Aldrich) and harvested 4 h after stimulation. The culture supernatants were collected by centrifugation and aliquoted into small sterile tubes. All the samples were stored at −80 °C until assayed for cytokines.
Enzyme-linked immunosorbent assay
The levels of IL-1 and IL-6 of supernatant samples were measured on duplicate samples using Quantikine® ELISA kits (R&D Systems Europe, Abingdon, U.K.) according to the manufacturer’s instructions.
Monocyte migration assay
Monocyte chemoattractant activity was assessed using 24-well TransWell® plates with 5-μm pore filters (Corning Incorporated, Corning, NY). CAV-1-silenced monocytes (5 × 103) or controlled monocytes (5 × 103) were placed in the upper compartment of each chamber. RPMI-1640 supplemented with 1% FBS in either the presence or absence of 100 ng/ml MCP-1 (Thermo Fisher Scientific) was added into the lower compartment. Cells were allowed to migrate through the filter for 90 min at 37 °C and then harvested from both compartments and manually counted with a haemocytometer. Percentage of migrated cell was calculated as ratio of the cell count of the lower compartment to the total cell count of the upper and lower compartments.
Murine model of psoriasis-like skin inflammation
For in vivo experiments, 6-week-old C57BL/6 J female mice (Japan SLC, Shizuoka, Japan) were used. IMQ was used to induce skin inflammation as previously described3. A daily dose of 62.5 mg of 5% IMQ cream (Beselna® cream; Mochida Pharmaceutical, Tokyo, Japan) was applied to the back skin of mice for 10 consecutive days. Vaseline was used as control. On another psoriasis-like murine model, IL-23 was used to induce skin inflammation as previously described33. Twenty millilitres of PBS containing 500 ng recombinant mouse IL-23 (BioLegend, San Diego, CA) or the same amount of PBS alone was intradermally administered into ears every other day for 10 days. All animal experiments were performed after approval by Yokohama City University Institutional Animal Care and Use Committee (Approval No: F-A-16–087), and in accordance with relevant guidelines and regulations.
CSD peptide treatment
Peptides corresponding to the CSD (DGIWKASFTTFTVTKYWFYR) and a scrambled control peptide (Ctr: WGIDKAFFTTSTVTYKWFRY) fused to the antennapedia internalization sequence (RQIKIWFQN RRMKWKK) were synthesized and dissolved in dimethyl sulfoxide. For injection, peptides were diluted in PBS, and 100 μl of 0.1 mM solution of the CSD or Ctr peptide was injected into mice intraperitoneally from day 1 (the first day of IMQ or IL-23 treatment) to day 10.
Harvesting blood and skin samples in murine model
Peripheral blood was collected by cardiac puncture in the presence of heparin at day 11. Blood was subjected to density gradient separation on Lympholyte® Mammal (Cedarlane, Burlington, Ontario, Canada) and centrifuged at 800 g for 20 min. PBMC layer was collected, and cell suspensions were prepared for PCR analyses as appropriate. Mice back skin where Vaseline or IMQ cream was applied was harvested at day 11 and homogenized with Micro SmashTM (TOMY SEIKO, Tokyo, Japan) for PCR analyses as appropriate.
Measurement of the clinical skin scores, epidermal thickness, and dermal macrophages in mice
The clinical skin score of IMQ-induced psoriasis inflammation mice was determined from day 1 (the first day of treatment) to day 11 using the modified psoriasis severity index score as previously described3. In IL-23-induced psoriasis-like mice, ear thickness was measured before injection on day 1 and thereafter for 10 days before injections. Ear measurements were made at the centre of the ears using an Adjustable Measuring Force Digimatic Micrometer (Mitutoyo, Kawasaki, Japan). All measurements were performed with blinding. Sections from paraffin-embedded mouse skin samples were stained with haematoxylin and eosin. The thickness of the epidermis was measured from the stratum basale to the stratum granulosum as previously described3. A number of infiltrated cells were also counted from 5 random fields of view of 10,000 μm2 for each mouse. Immunohistochemical analysis of CAV-1 was performed as previously described3. Briefly, sections were incubated with antibodies against CAV-1 (Santa Cruz Biotechnology) or isotype controls. The antigen was detected using EnVision Dual Link System-HRP or LSAB2 system-HRP, and AEC+ high sensitivity substrate chromogen was applied (Dako, Carpinteria, CA). Dermal macrophages were validated by immunofluorescent staining. Frozen cryosections of skin were stained with anti-F4/80 (Bio-Rad, Hercules, CA) and anti-CAV-1, followed by Alexa Flour® 633- and 488-conjugated secondary IgG, respectively. The intensity of CAV-1 staining in macrophages was quantified at the average of 10 infiltrated F4/80+ cells of 10 random fields for each mouse.
Statistical comparisons were performed using Mann-Whitney U test, unpaired Student’s t-test, Wilcoxon test, or one-way analysis of variance (post-hoc Tukey or Dunnett) as indicated. All tests were carried out using GraphPad Prism version 7.0 software (GraphPad Software, San Diego, CA). A P value < 0.05 was considered significant.
Griffiths, C. E. & Barker, J. N. Pathogenesis and clinical features of psoriasis. Lancet 370, 263–271, https://doi.org/10.1016/s0140-6736(07)61128-3 (2007).
Lowes, M. A., Bowcock, A. M. & Krueger, J. G. Pathogenesis and therapy of psoriasis. Nature 445, 866–873, https://doi.org/10.1038/nature05663 (2007).
Yamaguchi, Y., Watanabe, Y., Watanabe, T., Komitsu, N. & Aihara, M. Decreased Expression of Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in Mice. J Invest Dermatol 135, 2764–2774, https://doi.org/10.1038/jid.2015.249 (2015).
Kiss, A. L., Turi, A., Mullner, N. & Timar, J. Caveolin isoforms in resident and elicited rat peritoneal macrophages. Eur J Cell Biol 79, 343–349, https://doi.org/10.1078/s0171-9335(04)70038-2 (2000).
Yan, S. R., Fumagalli, L. & Berton, G. Activation of SRC family kinases in human neutrophils. Evidence that p58C-FGR and p53/56LYN redistributed to a Triton X-100-insoluble cytoskeletal fraction, also enriched in the caveolar protein caveolin, display an enhanced kinase activity. FEBS letters 380, 198–203, https://doi.org/10.1016/0014-5793(96)00029-4 (1996).
Shin, J. S., Gao, Z. & Abraham, S. N. Involvement of cellular caveolae in bacterial entry into mast cells. Science 289, 785–788, https://doi.org/10.1126/science.289.5480.785 (2000).
Harris, J., Werling, D., Hope, J. C., Taylor, G. & Howard, C. J. Caveolae and caveolin in immune cells: distribution and functions. Trends in immunology 23, 158–164, https://doi.org/10.1016/S1471-4906(01)02161-5 (2002).
Wang, X. M., Kim, H. P., Song, R. & Choi, A. M. Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol 34, 434–442, https://doi.org/10.1165/rcmb.2005-0376OC (2006).
Tourkina, E. et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 69, 1220–1226, https://doi.org/10.1136/ard.2009.117580 (2010).
Schonle, A. et al. Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. Blood 127, 1930–1939, https://doi.org/10.1182/blood-2015-09-672428 (2016).
Engel, D. et al. Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response. FASEB J 25, 3838–3848, https://doi.org/10.1096/fj.11-183350 (2011).
Zhu, T., Meng, Q., Ji, J., Zhang, L. & Lou, X. TLR4 and Caveolin-1 in Monocytes Are Associated With Inflammatory Conditions in Diabetic Neuropathy. Clin Transl Sci 10, 178–184, https://doi.org/10.1111/cts.12434 (2017).
Deleuran, M. et al. Localization of monocyte chemotactic and activating factor (MCAF/MCP-1) in psoriasis. J Dermatol Sci 13, 228–236, https://doi.org/10.1016/S0923-1811(96)00539-7 (1996).
Fuentes-Duculan, J. et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130, 2412–2422, https://doi.org/10.1038/jid.2010.165 (2010).
Bucci, M. et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6, 1362–1367, https://doi.org/10.1038/82176 (2000).
Del Galdo, F. et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 58, 2854–2865, https://doi.org/10.1002/art.23791 (2008).
Takahashi, H., Tsuji, H., Hashimoto, Y., Ishida-Yamamoto, A. & Iizuka, H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 35, 645–649, https://doi.org/10.1111/j.1365-2230.2009.03704.x (2010).
Suarez-Farinas, M. et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132, 2552–2564, https://doi.org/10.1038/jid.2012.184 (2012).
Kyriakou, A., Patsatsi, A., Vyzantiadis, T. A. & Sotiriadis, D. Serum levels of TNF-alpha, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity. J Immunol Res 2014, 467541, https://doi.org/10.1155/2014/467541 (2014).
Okubo, Y. & Koga, M. Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci 17, 223–232, https://doi.org/10.1016/S0923-1811(98)00019-X (1998).
Mizutani, H., Ohmoto, Y., Mizutani, T., Murata, M. & Shimizu, M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14, 145–153, https://doi.org/10.1016/S0923-1811(96)00562-2 (1997).
Mizutani, H., Ohmoto, Y., Tanaka, H. & Shimizu, M. Psoriatic monocytes respond sensitively to lipopolysaccharide but with limited inflammatory cytokine production. Archives of dermatological research 289, 657–659 (1997).
Yamanaka, K. et al. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils. J Dermatol 41, 679–685, https://doi.org/10.1111/1346-8138.12560 (2014).
Haines, P., Samuel, G. H., Cohen, H., Trojanowska, M. & Bujor, A. M. Caveolin-1 is a negative regulator of MMP-1 gene expression in human dermal fibroblasts via inhibition of Erk1/2/Ets1 signaling pathway. J Dermatol Sci 64, 210–216, https://doi.org/10.1016/j.jdermsci.2011.08.005 (2011).
Yi F, X. L. M. et al. Caveolin-1 Plays a Critical Role in the Differentiation of Monocytes into Macrophages. Arterioscler Thromb Vasc Biol. 32, e117–e125, https://doi.org/10.1161/ATVBAHA.112.254151 (2012).
Gillitzer, R. et al. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 101, 127–131, https://doi.org/10.1111/1523-1747.ep12363613 (1993).
Vestergaard, C., Just, H., Baumgartner Nielsen, J., Thestrup-Pedersen, K. & Deleuran, M. Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta dermato-venereologica 84, 353–358, https://doi.org/10.1080/00015550410034444 (2004).
Lembo, S. et al. MCP-1 in psoriatic patients: effect of biological therapy. J Dermatolog Treat 25, 83–86, https://doi.org/10.3109/09546634.2013.782091 (2014).
Pavlides, S. et al. Caveolin-1 regulates the anti-atherogenic properties of macrophages. Cell Tissue Res 358, 821–831, https://doi.org/10.1007/s00441-014-2008-4 (2014).
Weng, P. et al. Caveolin-1 scaffolding domain peptides enhance anti-inflammatory effect of heme oxygenase-1 through interrupting its interact with caveolin-1. Oncotarget 8, 40104–40114, https://doi.org/10.18632/oncotarget.16676 (2017).
Tourkina, E. et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 294, L843–861, https://doi.org/10.1152/ajplung.00295.2007 (2008).
Yamaguchi, Y., Yasuoka, H., Stolz, D. B. & Feghali-Bostwick, C. A. Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5. J Cell Mol Med 15, 957–969, https://doi.org/10.1111/j.1582-4934.2010.01063.x (2011).
Mabuchi, T. et al. CCR6 is required for epidermal trafficking of gammadelta-T cells in an IL-23-induced model of psoriasiform dermatitis. J Invest Dermatol 133, 164–171, https://doi.org/10.1038/jid.2012.260 (2013).
This work was supported by a grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Y. Yamaguchi.).
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.